Skip to main content
OpenTrials
Completed

NCT Number: NCT01290250

Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans

The purpose of this study is to evaluate the effects of a new orange juice-based beverage enriched in fiber and selected phenolic compounds (mainly flavanones) on features of metabolic syndrome and cardiovascular disease risk factors related to inflammation and antioxidant defense system in overweight and obese adult humans. This study hypothesizes that consumption of an orange juice-based beverage enriched in fiber and selected phenolic compounds (mainly flavanones)would improve lipid levels and lipid metabolism,blood pressure and the Homeostatic Model Assessment (HOMA) index.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology, Center for Biomedical Research, University of

Granada, 18071, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index (BMI) higher than 25 (overweight or obese) but lower than 40 (extreme obesity) or waist circumference higher than 94 cm for men and 80 cm for women,

and having altered at least two markers of MS namely:

  • Hypertension (diastolic pressure higher than 85 mmHg but lower than 110 mmHg)
  • Hyperglycemia (higher than 100 mg/dl but lower than 130 mg/dl)
  • Elevated plasma triacylglycerol concentrations (higher than 150 mg/dl)
  • Decreased plasma HDL-c levels (lower than 40 for men and 50 for women)
  • Volunteers will be otherwise healthy and without taking any medication aiming to lower either blood lipids, blood pressure or blood glucose concentrations.

Exclusion criteria

  • The presence of morbid obesity
  • Blood pressure higher than 110 mmHg
  • Plasma glucose levels higher than 130 mg/dl
  • The use of any medication for the control of blood pressure or glucose or lipid metabolism
  • Medical history of consumption of hypocaloric diet in the last year
  • Disorders of the food conduct
  • The presence of familiar dislipemias relatives of genetic character or the denial to take part in the study.

Treatment and study plan

Orange juice based beverage enriched in polyphenols

Other

2 daily doses (250 ml each) during 3 months

Primary outcomes

  1. Systolic blood pressure

    Time frame: 3 months

  2. Fasting Plasma Insulin Concentration

    Time frame: 3 months

  3. Fasting Plasma Triacylglycerols Concentration

    Time frame: 3 months

  4. Fasting Plasma High-Density Lipoprotein Cholesterol Concentration

    Time frame: 3 months

  5. Insulin resistance using HOMA (Homeostatic Model Assessment)index

    Time frame: 3 months

    The HOMA index will be calculated as the product of the fasting plasma insulin level (mU/mL) and the fasting plasma glucose level (mmol/L), divided by 22.5

  6. Fasting Plasma glucose concentrations

    Time frame: 3 months

  7. Diastolic blood pressure

    Time frame: 3 months

Secondary outcomes

  1. Antioxidant defense system

    Time frame: 3 months

    Biomarkers of the non-enzymatic (NE-ADS) and enzymatic antioxidant defense system (E-ADS). For the NE-ADS, in addition to total plasma antioxidant capacity, malondialdhyde, and total carbonyl protein derivatives, plasma α-tocopherol, β-carotene, retinol, coenzyme Q and total blood glutathione will be determined. Furthermore, the amount of plasma oxidized LDL and urinary 8-hydroxy-2'-deoxyguanosine and F2-isoprostanes will be measured. For E-ADS the activities of glutathione reductase, glutathione peroxidase, superoxide dismutase, and catalase in red blood cells will be assessed.

  2. Biomarkers of inflammation

    Time frame: 3 months

    Biomarkers of inflammation: Interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), matrix metalloproteinase-9 (MMP-9), monocyte chemotactic protein 1 (MCP-1)and polymorphonuclear neutrophils myeloperoxidase (MPO)

  3. Biomarkers of cardiovascular risk.

    Time frame: 3 months

    Biomarkers of cardiovascular risk:soluble endothelial selectin (sE-selectin), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule (sVCAM-1), total and active tissue plasminogen activator inhibitor-1 (tPAI-1), tumor necrosis factor alpha (TNF-α).

  4. Metabolic analysis

    Time frame: 3 months

    Gastrointestinal hormones involved in the control of satiety and insulin secretion i.e. active amylin, ghrelin (GHR), glucagon peptide-1 (GLP-1), gastric inhibitory peptide or gastric insulinotropic peptide (GIP), polypeptide YY 3-36, pancreatic polypeptide (PP).

    Likewise, adiponectin, leptin, resistin, visfatin, hepatocyte growth factor (HGF), nerve growth factor (NGF), retinol binding protein 4 (RBP4) and L-fatty acid binding protein (L-FABP) will be determined

  5. Gene expression analysis

    Time frame: 3 months

    Whole genome gene expression analysis: This analysis will be carried out in a subset of 20 control and 20 experimental samples at four times: 160 arrays. The GeneChip® Human Exon 1.0 ST will be used for the gene expression analysis.

    Validation by Reverse transcription polymerase chain reaction (RTPCR): In order to confirm the arrays results, a total of 93 differentially expressed genes in the experimental samples will be analyzed by RTPCR using low density arrays

Sponsors and collaborators

Lead sponsor

The Coca-Cola Company

Industry

Registry information

Official study title

Evaluation of a New Orange-Based Beverage Enriched With Polyphenols (Whole Press) on Features of Metabolic Syndrome and Cardiovascular Risk Factors Related to Inflammation and Antioxidant Defense System in Adult Humans

Acronym: BIONAOS

Important dates

Study start
2010
Primary completion
2011
Study completion
2012
First posted
Feb 4, 2011
Registry last updated
Mar 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.